Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy

Cheng Wang,1,* Min Han,1,2,* Xuerong Liu,1 Shaoqing Chen,1 Fuqiang Hu,1 Jihong Sun,3 Hong Yuan1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 2Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd, Hangzhou 310011, China; 3Department of Ra...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wang C, Han M, Liu X, Chen S, Hu F, Sun J, Yuan H
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/1fd4eeef28644b448fe512ab45c673ea
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:1fd4eeef28644b448fe512ab45c673ea
record_format dspace
spelling oai:doaj.org-article:1fd4eeef28644b448fe512ab45c673ea2021-12-02T09:08:35ZMitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy1178-2013https://doaj.org/article/1fd4eeef28644b448fe512ab45c673ea2019-02-01T00:00:00Zhttps://www.dovepress.com/mitoxantrone-preloaded-water-responsive-phospholipid-amorphous-calcium-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Cheng Wang,1,* Min Han,1,2,* Xuerong Liu,1 Shaoqing Chen,1 Fuqiang Hu,1 Jihong Sun,3 Hong Yuan1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 2Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd, Hangzhou 310011, China; 3Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China *These authors contributed equally to this work Background: The application of mitoxantrone (MIT) in cancer therapy has been severely limited by its inherent drawbacks. In addition, effective cancer therapy calls for drug release systems capable of enforcing drug release within cancer cells in response to infinite stimulant with enhanced drug penetration capability. Methods: MIT-preloaded phospholipid-amorphous calcium carbonate hybrid nanoparticles (PL/ACC-MIT) that surface modified with PL shell (containing shielding polymer polyethylene glycol and targeting moiety folic acid) were prepared by a facile solvent-diffusion method. Results: It has been proven that the resulting PL/ACC-MIT nanoparticles demonstrated satisfactory stability against various aqueous environments with minimal drug leakage and exerted strong targeting capability but selective preference to the folate receptor-overexpressing cell line. In contrast, once exposed to the enzyme-abundant and acidic environments of cancer cells, the PL/ACC-MIT nanoparticles can readily decompose to facilitate quick drug release and enhanced drug penetration to yield preferable antitumor effect both in vitro and in vivo. Conclusion: In this study, MIT-preloaded water-responsive hybrid nanoparticles with increased stability, targetability, controlled drug release, and enhanced drug penetration were successfully developed, which might be a candidate for targeted and effective cancer therapy. Keywords: mitoxantrone, water responsive, hybrid nanoparticles, amorphous calcium carbonate, cancer therapyWang CHan MLiu XChen SHu FSun JYuan HDove Medical Pressarticlemitoxantronewater responsivehybrid nanoparticlesamorphous calcium carbonatecancer therapyMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 1503-1517 (2019)
institution DOAJ
collection DOAJ
language EN
topic mitoxantrone
water responsive
hybrid nanoparticles
amorphous calcium carbonate
cancer therapy
Medicine (General)
R5-920
spellingShingle mitoxantrone
water responsive
hybrid nanoparticles
amorphous calcium carbonate
cancer therapy
Medicine (General)
R5-920
Wang C
Han M
Liu X
Chen S
Hu F
Sun J
Yuan H
Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
description Cheng Wang,1,* Min Han,1,2,* Xuerong Liu,1 Shaoqing Chen,1 Fuqiang Hu,1 Jihong Sun,3 Hong Yuan1 1Department of Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 2Hangzhou Zhongmei Huadong Pharmaceutical Co, Ltd, Hangzhou 310011, China; 3Department of Radiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China *These authors contributed equally to this work Background: The application of mitoxantrone (MIT) in cancer therapy has been severely limited by its inherent drawbacks. In addition, effective cancer therapy calls for drug release systems capable of enforcing drug release within cancer cells in response to infinite stimulant with enhanced drug penetration capability. Methods: MIT-preloaded phospholipid-amorphous calcium carbonate hybrid nanoparticles (PL/ACC-MIT) that surface modified with PL shell (containing shielding polymer polyethylene glycol and targeting moiety folic acid) were prepared by a facile solvent-diffusion method. Results: It has been proven that the resulting PL/ACC-MIT nanoparticles demonstrated satisfactory stability against various aqueous environments with minimal drug leakage and exerted strong targeting capability but selective preference to the folate receptor-overexpressing cell line. In contrast, once exposed to the enzyme-abundant and acidic environments of cancer cells, the PL/ACC-MIT nanoparticles can readily decompose to facilitate quick drug release and enhanced drug penetration to yield preferable antitumor effect both in vitro and in vivo. Conclusion: In this study, MIT-preloaded water-responsive hybrid nanoparticles with increased stability, targetability, controlled drug release, and enhanced drug penetration were successfully developed, which might be a candidate for targeted and effective cancer therapy. Keywords: mitoxantrone, water responsive, hybrid nanoparticles, amorphous calcium carbonate, cancer therapy
format article
author Wang C
Han M
Liu X
Chen S
Hu F
Sun J
Yuan H
author_facet Wang C
Han M
Liu X
Chen S
Hu F
Sun J
Yuan H
author_sort Wang C
title Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
title_short Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
title_full Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
title_fullStr Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
title_full_unstemmed Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
title_sort mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/1fd4eeef28644b448fe512ab45c673ea
work_keys_str_mv AT wangc mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT hanm mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT liux mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT chens mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT huf mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT sunj mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
AT yuanh mitoxantronepreloadedwaterresponsivephospholipidamorphouscalciumcarbonatehybridnanoparticlesfortargetedandeffectivecancertherapy
_version_ 1718398230814785536